Royalty Pharma Quarterly Income Statement
NASDAQ: RPRXHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Royalty Pharma revenue and earnings
In the quarter ended Jun 30, 2026, Royalty Pharma generated $674.1 million in revenue, up 16.5% from the same quarter a year earlier. Net income was $17.9 million (-44.4% year over year), for a net margin of 2.7% versus a median of 42.1% in the prior 5 quarters. Operating margin was 19.7%.
Diluted earnings per share came in at $0.04, down from $0.07.
Summary generated from market data by MetaCap's automated system. Methodology
Royalty Pharma income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 674.14M | 630.58M | 621.99M | 609.29M | 578.66M | 568.25M | 593.64M | 564.69M | 537.27M | 567.98M | 596.07M | 536.31M |
| Revenue growth (YoY) | +16.50% | +10.97% | +4.78% | +7.90% | +7.71% | +0.05% | -0.41% | +5.29% | -0.17% | -16.96% | +5.36% | -6.48% |
| Research & Development | 97.85M | 39.79M | 50.50M | 50.50M | 300.50M | 50.50M | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 50.50M |
| Operating Income | 133.12M | 563.04M | 388.38M | 427.16M | 209.80M | 534.18M | 361.51M | 735.07M | 269.63M | -73.77M | 612.90M | 151.44M |
| Interest Expense | 93.62M | 93.72M | 94.17M | 79.56M | 68.67M | 65.26M | 65.76M | 66.51M | 49.01M | 44.23M | 47.26M | 46.03M |
| Other Income (Expense) | -51.63M | -94.78M | -32.47M | 17.05M | -117.16M | -99.75M | -27.16M | 71.28M | -75.25M | 69.50M | 104.69M | -29.36M |
| Pretax Income | 81.49M | 468.26M | 355.91M | 444.21M | 92.64M | 434.43M | 334.35M | 806.36M | 194.38M | -4.27M | 717.59M | 122.08M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 17.88M | 294.69M | 214.21M | 288.22M | 32.18M | 239.35M | 208.21M | 543.99M | 102.00M | 4.78M | 494.34M | 72.11M |
| Net Income growth (YoY) | -44.42% | +23.12% | +2.88% | -47.02% | -68.46% | +4909.40% | -57.88% | +654.34% | -55.19% | -98.60% | — | -49.45% |
| EPS (Basic) | 0.04 | 0.67 | 0.49 | 0.67 | 0.08 | 0.55 | 0.46 | 1.22 | 0.23 | 0.01 | 1.11 | 0.16 |
| EPS (Diluted) | 0.04 | 0.67 | 0.49 | 0.67 | 0.07 | 0.55 | 0.46 | 1.21 | 0.23 | 0.01 | 1.11 | 0.16 |
| Shares Outstanding (Basic) | 445.06M | 436.79M | — | 431.89M | 423.51M | 435.48M | — | 447.63M | 451.02M | 448.62M | — | 448.44M |
| Shares Outstanding (Diluted) | 556.90M | 556.84M | — | 559.61M | 562.30M | 578.10M | — | 592.73M | 596.91M | 597.48M | — | 601.14M |
| EBITDA | 134.41M | 564.21M | 389.58M | 428.43M | 211.18M | 534.18M | 361.51M | 735.07M | — | — | — | — |
| Operating Margin | 19.75% | 89.29% | 62.44% | 70.11% | 36.26% | 94.01% | 60.90% | 130.17% | 50.19% | -12.99% | 102.82% | 28.24% |
| Net Margin | 2.65% | 46.73% | 34.44% | 47.30% | 5.56% | 42.12% | 35.07% | 96.33% | 18.99% | 84.00% | 82.93% | 13.45% |
This table shows 12 quarterly periods of Royalty Pharma's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow RPRX's reporting calendar. What is a income statement?